An Open Label Phase 2 Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel Delivered Every 14 Days With Pegfilgrastim and Darbepoetin Alfa Support for the Adjuvant Treatment of Women With Breast Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The proportion of subjects experiencing any delay in any cycle of chemotherapy over the course of the study
3 months
No
MD
Study Director
Amgen
Australia: Therapeutic Goods Administration
20040137
NCT00261313
December 2005
December 2007
Name | Location |
---|